文献速递免疫规划传染病防控与疫情报告

刚果(金)医护人员接种rVSV-ZEBOV疫苗后对埃博拉病毒及疫苗载体的长期抗体应答

Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC.
PubMed 文献 · Vaccine · 2025-07-23

在刚果(金)医护人员中开展的横断面研究,共纳入133名既往在不同疫情中接种rVSV-ZEBOV疫苗者及20名未接种对照,按接种后1–2年、2–3年、>3年分组。结果显示针对Kikwit株糖蛋白的血清阳性率在接种后1–2年为100%,>3年降至76.8%,而Mayinga和Kissidougou株的阳性率较低;仅少数高抗体滴度者仍可检测到中和能力。作者认为数据支持在接种后1–2年给予加强剂以获得最佳保护。

要点

  • 接种后1–2年组(n=10)针对Kikwit株糖蛋白血清阳性率为100%。
  • 接种>3年者血清阳性率:Kikwit 76.8%、Mayinga 38.3%、Kissidougou 44.6%。
  • 仅少数(n=6)高抗体滴度医护人员仍可检测到中和能力。

核心结论

  • 结果提示接种后长达4年仍可检测到针对埃博拉病毒糖蛋白的抗体应答,但呈株特异性且缓慢下降。
  • 数据支持在接种后1–2年给予加强剂以获得最佳保护,并提示疫苗诱导免疫可能具有株限制性。

研究设计与样本

  • 横断面研究,在刚果(金)招募既往在不同疫情中接种rVSV-ZEBOV疫苗的医护人员133名,按接种后时间分为1–2年、2–3年、>3年组,另设20名未接种医护人员为对照。
  • 通过检测针对三种Orthoebolavirus zaïrense毒株的抗体持久性和中和能力,以及通过VSV蛋白血清阳性评估载体定向免疫。

主要发现

  • 接种后1–2年组(n=10)针对疫苗靶向的Kikwit株埃博拉病毒糖蛋白总体抗体应答高(血清阳性率100%),而针对Mayinga和Kissidougou株糖蛋白的血清阳性率<50%。
  • 该抗体趋势持续至接种后4年,但接种>3年者总体血清阳性率降至Kikwit 76.8%、Mayinga 38.3%、Kissidougou 44.6%。
  • 所有时间组中仅少数(n=6)高抗体滴度医护人员仍可检测到中和能力。
  • 任何时间点均未观察到持续的VSV特异性抗体应答,提示对加强剂次的干扰无或低。

关键数值与推荐

  • 接种后1–2年组(n=10)针对Kikwit株糖蛋白血清阳性率为100%。
  • 接种>3年者血清阳性率:Kikwit 76.8%、Mayinga 38.3%、Kissidougou 44.6%。
  • 所有时间组中仅n=6名高抗体滴度者仍可检测到中和能力。

临床怎么用

  • 作者认为数据支持在接种后1–2年给予加强剂以获得最佳保护。
  • 作者指出疫苗诱导免疫可能具有株限制性,并可能为长期保护的相关因素提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Zaïre ebolavirus (EBOV) remains a serious threat with a high case fatality rate in humans, particularly in the Democratic Republic of Congo (DRC). To cope with previous epidemics, the single-dose and prophylactic rVSV-ZEBOV vaccine was widely applied. However, evidence on the duration of protection and, consequently, the need or timing for booster doses is lacking. Therefore, we investigated in a cross-sectional study design the antibody persistence and neutralizing capacity against three strains of the Orthoebolavirus zaïrense species within healthcare workers (HCWs) who were previously vaccinated in different outbreaks across DRC. The presence of vector-directed immunity was studied via seropositivity to VSV proteins. In total, 133 HCWs were recruited and grouped according to their time from initial vaccination (1-2, 2-3, >3 years), in addition to a control group of 20 unvaccinated HCWs. In 1-2 year vaccinated participants (n = 10), an overall high antibody response (100 % seropositivity) specific to the vaccine-targeted EBOV glycoprotein (GP) of the Kikwit strain was observed, in comparison to <50 % seropositivity to the Mayinga and Kissidougou GP EBOV variants. This antibody trend persisted up to 4 years after vaccination, but overall seropositivity rates decreased to 76.8 % (Kikwit), 38.3 % (Mayinga), and 44.6 % (Kissidougou) for participants vaccinated >3 years ago. Only a minority (n = 6) among all time groups of HCWs with high antibody titers still had demonstrable neutralizing capacity. No persistent VSV-specific antibody responses were observed at any time, suggesting no to low interference with booster doses. Complementing prior findings, our results thus suggest a persistently detectable but strain-specific and slowly declining antibody response to EBOV up to 4 years after vaccination. Our data supports the administration of booster doses after 1-2 years for optimal protection, highlights potential strain-restrictive vaccine-induced immunity, and may inform on correlates of long-term protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kahusu CM, Peckeu-Abboud L, Goovaerts O, et al. Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC. Vaccine. 2025. PMID: 40706506. doi:10.1016/j.vaccine.2025.127537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。